HINGHAM, Mass., Feb. 04, 2021 (World NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) has gained official notification from the Japan Patent Office environment (JPO) that it intends to grant the Firm a patent for its ‘One & Done’ guidewire technologies for use with endoluminal interventions. Japan is the second jurisdiction to grant a patent for the ‘One & Done’ guidewire technologies and more protects the novel engineering the Company is at the moment establishing.
“We are advancing our LIBERTY™ Robotic system, exclusively the ‘One &Done’ technological innovation, and we are fully commited to build and safe limitations of entry through safeguarding our intellectual property and know-how,” commented Harel Gadot, CEO, President and Chairman. “We have been given favourable medical professional and business comments given that unveiling the LIBERTY Robotic process very last year, and we will integrate their shared viewpoint as we broaden our IP system.”
The permitted claims cover a double guidewire (movable core guidewire) comprising a initially hollow guidewire (outer tube) and a 2nd guidewire (interior main) deployed within the first guidewire (outer tube), and an adjuster mechanism operable to displace the 2nd guidewire (internal core) longitudinally relative to the first guidewire between at least 3 states. Just about every these condition is characterised with its distal suggestion curvature and stiffness.
Globally, the Corporation now holds a full of 41 patents issued/allowed and 22 pending patent programs.
About Microbot Health-related
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-scientific healthcare device firm that specializes in transformational micro-robotic systems, focused principally on each natural and artificial lumens inside of the human physique. Microbot’s existing proprietary technological platforms deliver the basis for the development of a Multi Generation Pipeline Portfolio (MGPP).
Microbot Healthcare was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of increasing clinical results for clients and raising accessibility through the use of micro-robotic systems. Further information about Microbot Healthcare is available at https://www.microbotmedical.com.
Statements pertaining to the registered direct presenting, timing, the total and expected use of proceeds and statements pertaining to long term financial and/or working benefits, long term growth in analysis, engineering, clinical improvement, and likely alternatives for Microbot Health-related Inc. and its subsidiaries, together with other statements about the foreseeable future expectations, beliefs, objectives, options, or prospective buyers expressed by administration, represent ahead-hunting statements inside the that means of the Non-public Securities Litigation Reform Act of 1995 and the Federal securities guidelines. Any statements that are not historical actuality (including, but not restricted to statements that incorporate terms these kinds of as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) really should also be regarded to be forward-looking statements. Ahead-seeking statements entail challenges and uncertainties, like, without limitation, marketplace ailments and the fulfillment of customary closing problems, risks inherent in the improvement and/or commercialization of potential items, including LIBERTY and SCS, the final result of its scientific studies to consider LIBERTY, SCS and other current and long run technologies, uncertainty in the effects of pre-clinical and medical trials or regulatory pathways and regulatory approvals, uncertainty resulting from the COVID-19 pandemic, have to have and capability to receive foreseeable future funds, and upkeep of mental property legal rights. Extra info on risks facing Microbot Health-related can be identified under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are out there on the SEC’s net web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, besides as required by legislation.
Trader Speak to: